Approaches to Three-Dimensional Quantitative Structure-Activity Relationships

Reviews in Computational Chemistry

Volumn 11, Issue , 1997, Pages 183-240

  Greco, Giovanni ^a   Novellino, Ettore ^b   Martin, Yvonne Connolly ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c Pharmaceutical Products Division ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031527565     PISSN: 10693599     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (244)

1. H. Kubinyi, Ed., 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993, pp. 759. S. M. Green and G. R. Marshall, Trends Pharmacol. Sci., 16, 285 (1995). 3D-QSAR - A Current Perspective.
2. H. Kubinyi, Ed., 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993, pp. 759. S. M. Green and G. R. Marshall, Trends Pharmacol. Sci., 16, 285 (1995). 3D-QSAR - A Current Perspective.
3. T. I. Oprea and C. L. Waller, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 127-182. Theoretical and Practical Aspects of Three-Dimensional Quantitative Structure-Activity Relationships.
4. C. Hansch and A. Leo, Exploring QSAR: Fundamentals and Applications in Chemistry and Biology, American Chemical Society, Washington, DC, 1995.
5. C. Hansch, A. Leo, and D. Hoekman, Exploring QSAR: Hydrophobic, Electronic, and Steric Constants, American Chemical Society, Washington, DC, 1995.
6. Y. C. Martin, Quantitative Drug Design, Dekker, New York, 1978.
7. 3 Probes Using Comparative Molecular Field Analysis (CoMFA) and the Modified PLS Method.
8. K. H. Kim and D. H. Kim, Bioorg. Med. Chem., 3, 1389 (1995). Description of Hydrophobicity Parameters of a Mixed Set from Their 3-Dimensional Structures.
9. K. Kim, J. Comput.-Aided Mol. Design, 9, 308 (1995). Calculation of Hydrophobic Parameters Directly from 3-Dimensional Structures Using Comparative Molecular-Field Analysis.
10. K. H. Kim, in Trends in QSAR and Molecular Modelling '92, C.-G. Wermuth, Ed., ESCOM, Leiden, 1993, pp. 245-251. Use of the Hydrogen-Bond Potential Function in Comparative Molecular Field Analysis (CoMFA): An Extension of CoMFA.
11. K. H. Kim, J. Comput.-Aided Mol. Design, 7, 71 (1993). Non-linear Dependence in Comparative Molecular Field Analysis.
12. a's) of Clonidine-like Imidazolines, 2-Substituted Imidazoles, and 1-Methyl-2-substituted-imidazoles from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA) Approach.
13. K. H. Kim and Y. C. Martin, J. Org. Chem., 56, 2723 (1991). Direct Prediction of Linear Free Energy Substituent Effects from 3D Structures Using Comparative Molecular Field Analysis. 1. Electronic Effects of Substituted Benzoic Acids.
14. K. H. Kim, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 619-642. Comparison of Classical and 3D QSAR.
15. K. H. Kim, G. Greco, E. Novellino, C. Silipo, and A. Vittoria, J. Comput.-Aided Mol. Design, 7, 263 (1993). Use of the Hydrogen Bond Potential Function in a Comparative Molecular Field Analysis (CoMFA) on a Set of Benzodiazepines.
16. K. H. Kim, Quant. Struct.-Act. Relat., 11, 127 (1992). 3D-Quantitative Structure-Activity Relationships: Description of Electronic Effects Directly from 3D Structures Using a GRID-Comparatwe Molecular Field Analysis (CoMFA) Approach.
17. K. H. Kim, Quant. Struct.-Act. Relat., 11, 453 (1992). 3D-Quantitative Structure-Activity Relationships: Investigation of Steric Effects with Descriptors Directly from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA) Approach.
18. K. H. Kim, Quant. Struct.-Act. Relat., 11, 309 (1992). 3D-Quantitative Structure-Activity Relationships: Nonlinear Dependence Described Directly from 3D Structures Using Comparative Molecular Field Analysis (CoMFA).
19. K. H. Kim Med. Chem. Res., 2, 22 (1992). Description of Nonlinear Dependence Directly from 3D Structures in 3D-Quantitative Structure-Activity Relationships.
20. K. H. Kim, Med. Chem. Res., 1, 259 (1991). A Novel Method of Describing Hydrophobic Effects Directly from 3D Structures in 3D-Quantitative Structure-Activity Relationships Study.
21. G. Greco, E. Novellino, C. Silipo, and A. Vittoria, Quant. Struct.-Act. Relat., 11, 461 (1992). Study of Benzodiazepine Receptor Sites Using a Combined QSAR-CoMFA Approach.
22. A. K. Debnath, C. Hansch, K. H. Kim, and Y. C. Martin, J. Med. Chem., 36, 1007 (1993). Mechanistic Interpretation of the Genotoxicity of Nitrofurans as Antibacterial Agents Using Quantitative Structure-Activity Relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA).
23. A. Carrieri, C. Altomare, M. L. Barreca, A. Contento, A. Carotti, and C. Hansch, Farmaco, 49, 573 (1994). Papain Catalyzed Hydrolysis of Aryl Esters: A Comparison of the Hansch, Docking, and CoMFA Methods.
24. D. C. Horwell, W. Howson, M. Higginbottom, D. Naylor, G. S. Ratcliffe, and S. Williams, J. Med. Chem., 38, 4454 (1995). Quantitative Structure-Activity-Relationships (QSARs) of N-Terminus Fragments of NK1 Tachykinin Antagonists: A Comparison of Classical QSARs and Three-Dimensional QSARs from Similarity Matrices.
25. J. G. Topliss and R. P. Edwards, J. Med. Chem., 22, 1238 (1979). Chance Factors in Studies of Quantitative Structure-Activity Relationships.
26. M. Clark and R. D. Cramer III, Quant. Struct.-Act. Relat., 12, 137 (1993). The Probability of Chance Correlation Using Partial Least Squares (PLS).
27. C. T. Lin, P. A. Pavlik, and Y. C. Martin, Tetrahedron Comput. Methodol., 3, 723 (1990). Use of Molecular Fields to Compare Series of Potentially Bioactive Molecules Designed by Scientists or by Computer.
28. C. Hansch, S. H. Unger, and A. B. Forsythe, J. Med. Chem., 16, 1212 (1973). Strategy in Drug Design. Cluster Analysis as an Aid in the Selection of Substituents.
29. Y. C. Martin and H. N. Panas, J. Med. Chem., 22, 784 (1979). Mathematical Considerations in Series Design.
30. U. Norinder, J. Comput.-Aided Mol. Design, 4, 381 (1990). Experimental Design Based 3-D QSAR Analysis of Steroid-Protein Interactions: Application to Human CBG Complexes.
31. G. Caliendo, G. Greco, E. Novellino, E. Perissutti, and V. Santagada, Quant. Struct.-Act. Relat., 13, 249 (1994). Combined Use of Factorial Design and Comparative Molecular Field Analysis (CoMFA): A Case Study.
32. H. Kubinyi and U. Abraham, in JD QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 717-728. Practical Problems in PLS Analyses.
33. M. C. Nicklaus, S. Wang, J. S. Driscoll, and G. W. A. Milne, Bioorg. Med. Chem., 3, 411 (1995). Conformational Changes of Small Molecules Binding to Proteins.
34. G. Klebe, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 173-199. Structural Alignment of Molecules.
35. Y. C. Martin, in Designing Bioactive Molecules: Three-Dimensional Techniques and Applications, P. Willett and Y. C. Martin, Eds., American Chemical Society, Washington, DC, 1997, in press. Pharmacophore Mapping.
36. G. R. Marshall, C. D. Barry, H. E. Bosshard, R. A. Dammkoehler, and D. A. Dunn, in Computer-Assisted Drug Design, E. C. Olson and R. E. Christoffersen, Eds., American Chemical Society, Washington, 1979, pp. 205-226. The Conformation Parameter in Drug Design: The Active Analog Approach.
37. SYBYL Molecular Modeling Software, Tripos, Inc., 1699 S. Hanley Road, St Louis, MO 63944.
38. J. M. Blaney, G. M. Crippen, A. Dearing, and J. S. Dixon, DGEOM, Distance Geometry, QCPE 590, Quantum Chemistry Program Exchange, Indiana University, Bloomington, IN 47405.
39. G. Crippen, Distance Geometry and Conformational Calculations, Research Studies Press, Letchworth, UK, 1981. G. M. Crippen and T. F. Havel, Distance Geometry and Molecular Conformation, Wiley, New York, 1988.
40. G. Crippen, Distance Geometry and Conformational Calculations, Research Studies Press, Letchworth, UK, 1981. G. M. Crippen and T. F. Havel, Distance Geometry and Molecular Conformation, Wiley, New York, 1988.
41. J. M. Blaney and J. S. Dixon, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1994, Vol. 5, pp. 299-335. Distance Geometry in Molecular Modeling.
42. R. P. Sheridan, R. Nilakantan, J. S. Dixon, and R. Venkataraghavan, J. Med. Chem., 29, 899 (1986). The Ensemble Approach to Distance Geometry: Application to the Nicotinic Pharmacophore.
43. Y. C. Martin, M. G. Bures, E. A. Danaher, J. DeLazzer, I. Lico, and P. A. Pavlik, J. Comput.-Aided Mol. Design, 7, 83 (1993). A Fast New Approach to Pharmacophore Mapping and Its Application to Dopaminergic and Benzodiazepine Agonists.
44. APEX-3D, 1.3, Molecular Simulations, Inc. (formerly BIOSYM Technologies), San Diego, CA.
45. V. E. Golender and E. R. Vorpagel, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 137-149. Computer-Assisted Pharmacophore Identification.
46. Hypotheses in Catalyst, Molecular Simulations, Inc. (formerly BioCAD), San Diego, CA.
47. Y. Kato, A. Itai, and Y. Iitaka, Tetrahedron, 43, 5229 (1987). A Novel Method for Superimposing Molecules and Receptor Mapping.
48. A. Itai, Y. Kato, N. Tomioka, Y. Iitaka, Y. Endo, M. Hasegawa, K. Shudo, H. Fujiki, and S.-I. Saka, Proc. Natl. Acad. Sci. USA, 85, 3688 (1988). A Receptor Model tor Tumor Promoters: Rational Superposition of Teleocidins and Phorbol Esters.
49. R. C. Wade, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 486-506. Molecular Interaction Fields.
50. A. N. Jain K. Koile, and D. Chapman, J. Med. Chem., 37, 2315 (1994). Compass: Predicting Biological Activities from Molecular Surface Properties. Performance Comparisons on a Steroid Benchmark.
51. A. N. Jain, T. G. Dietterich, R. H. Lathrop, D. Chapman, R. E. Critchlow Jr., B. E. Bauer, T. A. Webster, and T. Lozano-Perez, J. Comput.-Aided Mol. Design, 8, 635 (1994). Compass: A Shape-Based Machine Learning Tool for Drug Design.
52. S. K. Kearsley and G. M. Smith, Tetrahedron Comput. Methodol., 3, 615 (1990). An Alternative Method for the Alignment of Molecular Structures: Maximizing Electrostatic and Steric Overlap.
53. S. K. Kearsley and G. M. Smith, SEAL, An Alternate Method for the Alignment of Molecular Structures, QCPE 634, Quantum Chemistry Program Exchange, Indiana University, Bloomington, IN 47405.
54. R. B. Hermann and D. K. Herron, J. Comput.-Aided Mol. Design, 5, 511 (1991). OVID and SUPER: Two Overlap Programs for Drug Design.
55. C. Burt, W. G. Richards, and P. Huxley, J. Comput. Chem., 11, 1139 (1990). The Application of Molecular Similarity Calculations.
56. A. M. Doweyko, J. Med. Chem., 31, 1396 (1988). The Hypothetical Active Site Lattice. An Approach to Modelling Active Sites from Data on Inhibitor Molecules.
57. M. Clark, R. D. Cramer III, D. M. Jones, D. E. Patterson, and P. E. Simeroth, Tetrahedron Comput. Methodol., 3, 47 (1990). Comparative Molecular Field Analysis (CoMFA). 2. Toward Its Use with 3D-Structural Databases.
58. F. Sanz, F. Manaut, J. Rodriguez, E. Lozoya, and E. Lopez-de-Briñas, J. Comput.-Aided Mol. Design, 7, 337 (1993). MEPSIM: A Computational Package for Analysis and Comparison of Molecular Electrostatic Potentials.
59. G. Klebe and U. Abraham, J. Med. Chem., 36, 70 (1993). On the Prediction of Binding Properties of Drug Molecules by Comparative Molecular Field Analysis.
60. T. I. Oprea, C. L. Waller, and G. R. Marshall, J. Med. Chem., 37, 2206 (1994). Three-Dimensional Quantitative Structure-Activity Relationship of Human Immunodeficiency Virus (I) Protease Inhibitors. 2. Predictive Power Using Limited Exploration of Alternate Binding Modes.
61. S. Wold, A. Ruhe, H. Wold, and W. J. Dunn, SIAM J. Sci. Stat. Comput., 5, 735 (1984). The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses.
62. S. Wold, E. Johansson, and M. Cocchi, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 523-550. PLS - Partial Least-Squares Projections to Latent Structures.
63. B. L. Bush and R. B. Nachbar Jr., J. Comput.-Aided Mol. Design, 7, 587 (1993). Sample-Distance Partial Least-Squares - PLS Optimized for Many Variables, with Application to CoMFA.
64. B. L. Bush, SAMPLS, SAMple-distance Partial Least Squares, QCPE 650, V. 1.3, Quantum Chemistry Program Exchange, Indiana University, Bloomington, IN 47405.
65. R. D. Cramer III, J. D. Bunce, D. E. Patterson, and I. E. Frank, Quant. Struct.-Act. Relat., 7, 8 (1988). Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies.
66. S. Wold, Technometrics, 20, 397 (1978). Cross-Validatory Estimation of the Number of Components in Factor and Principal Component Models.
67. M. Baroni, G. Costantino, G. Cruciani, D. Riganelli, R. Valigi, and S. Clementi, Quant. Struct.-Act. Relat., 12, 9 (1993). Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Tool for Handling 3D-QSAR Problems.
68. B. Cruciani, S. Clementi, and M. Baroni, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 551-564. Variable Selection in PLS Analysis.
69. G. Cruciani and K. A. Watson, J. Med. Chem., 37, 2589 (1994). Comparative Molecular Field Analysis Using GRID Force-Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b.
70. M. S. Allen, A. J. LaLoggia, L. J. Dorn, M. J. Martin, G. Costantino, T. J. Hagen, K. F. Koehler, P. Skolnick, and J. M. Cook, J. Med. Chem., 35, 4001 (1992). Predictive Binding of β-Carboline Inverse Agonists and Antagonists via the CoMFA/GOLPE Approach.
71. A. R. Ortiz, M. T. Pisabarro, F. Gago, and R. C. Wade, J. Med. Chem., 38, 2681 (1995). Prediction of Drug Binding Affinities by Comparative Binding Energy Analysis.
72. 2-Guided Region Selection for Comparative Molecular Field Analysis: A Simple Method to Achieve Consistent Results.
73. U. Norinder, J. Chemometrics, 10, 95 (1996). Single and Domain Mode-Variable Selection in 3D QSAR Applications.
74. G. Cruciani, S. Clementi, and M. Pastor, in 3D QSAR in Drug Design. Recent Advances, H. Kubinyi, G. Folkers, and Y. Martin, Eds., ESCOM, Leiden, 1997, in press. GOLPE-Guided Region Selection.
75. H. Kubinyi, Quant. Struct.-Act. Relat., 13, 285 (1994). Variable Selection in QSAR Studies. I. An Evolutionary Algorithm.
76. D. E. Clark and D. R. Westhead, J. Comput.-Aided Mol. Design, 10, 337 (1996). Evolutionary Algorithms in Computer-Aided Molecular Design.
77. J. H. Holland, Sci. Am., 267, July 1992, p. 66. Genetic Algorithms.
78. R. Judson, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1996, Vol. 10, pp. 1-73. Genetic Algorithms and Their Use in Chemistry.
79. D. Rogers and A. J. Hopfinger, J. Chem. Inf. Comput. Sci., 34, 854 (1994). Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships.
80. W. J. Dunn III and D. Rogers, in Genetic Algorithms in Molecular Modeling, J. Devillers, Ed., Academic Press, New York, 1996, pp. 109-130. Genetic Partial Least Squares in QSAR.
81. Ajay, J. Med. Chem., 36, 3565 (1993). A Unified Framework for Using Neuronal Networks to Build QSARs.
82. J. Gasteiger and J. Zupan, Angew. Chem., Int. Ed. Engl., 32, 503 (1993). Neural Networks in Chemistry.
83. A. C. Good, S. S. So, and W. G. Richards, J. Med. Chem., 36, 433 (1993). Structure-Activity Relationships from Molecular Similarity-Matrices.
84. A. J. Harget and N. Bodor, in Personal Computers and Intelligent Systems: Information Processing 92, F. H. Vogt, Ed., Elsevier Science Publishers, North Holland, Amsterdam. 1992, Vol. 3, pp. 252-258. Computer-Aided Drug Design: A Neural Network Approach.
85. B. Joseph, F. H. Wang, and D. S. S. Shieh, Comput. Chem. Eng., 16, 413 (1992). Exploratory Data Analysis: A Comparison of Statistical Methods with Artificial Neural Networks.
86. D. W. Salt, N. Yildiz, D. J. Livingstone, and C. J. Tinsley, Pestic. Sci., 36, 161 (1992). The Use of Artificial Neural Networks in QSAR.
87. M. T. Spining, J. A. Darsey, B. G. Sumpter, and D. W. Noid, J. Chem. Educ. 71, 406 (1994). Opening Up the Black Box of Artificial Neural Networks.
88. D. T. Manallack and D. J. Livingstone, Pestic. Sci., 45, 167 (1995). Relating Biological Activity to Chemical Structure Using Neural Networks.
89. T. R. Holcomb and M. Morari, Comput. Chem. Eng., 16, 393 (1992). PLS Neural Networks.
90. S. J. Qin and T. J. McAvoy, Comput. Chem. Eng., 16, 379 (1992). Nonlinear PLS Modeling Using Neural Networks.
91. D. T. Manallack, D. D. Ellis, and D. J. Livingstone, J. Med. Chem., 37, 3758 (1994). Analysis of Linear and Nonlinear QSAR Data Using Neural Networks.
92. J. H. Wikel and E. R. Dow, Bioorg. Med. Chem. Lett., 3, 645 (1993). The Use of Neural Networks for Variable Selection in QSAR.
93. D. Livingstone and D. T. Manallack, J. Med. Chem., 36, 1295 (1993). Statistics Using Neural Networks: Chance Effects.
94. I. V. Tetko, D. J. Livingstone, and A. I. Luik, J. Chem. Inf. Comput. Sci., 35, 826 (1995). Neural-Network Studies. 1. Comparison of Overfitting and Overtraining.
95. S. R. Krystek, Jr., J. T. Hunt, P. D. Stein, and T. R. Stouch, J. Med. Chem., 38, 659 (1995). Three-Dimensional Quantitative Structure-Activity Relationships of Sulfonamide Endothelin Inhibitors.
96. H.-D. Höltje and L. B. Kier, J. Pharm. Sci., 63, 1722 (1974). Sweet Taste Receptor Studies Using Model Interaction Energy Calculations.
97. H.-D. Höltje and L. B. Kier, J. Pharm. Sci., 64, 418 (1975). Nature of Anionic or α-Site of Cholinesterase.
98. J. P. Snyder, S. N. Rao, K. F. Koehler, and R. Pellicciari, in Trends in Receptor Research, P. Angeli, U. Gulini, and W. Quaglia, Eds., Elsevier, Amsterdam, 1992, pp. 367-403. Drug Modeling at Cell Membrane Receptors: The Concept of Pseudoreceptors.
99. H.-D. Höltje and M. Tintelnot, Quant. Struct.-Act. Relat., 3, 6 (1984). Theoretical Investigations on Interactions Between Pharmacon Molecules and Receptor Models. V. Construction of a Model for Ribosomal Binding Site of Chloramphenicol.
100. H.-D. Höltje and S. Marrer, Quant. Struct.-Act. Relat., 7, 174 (1988). Qualitative and Quantitative Structure-Activity Relationships for Calcium Channel Modulating 1,4-Dihydropyridine Derivatives: A Hypothetical Molecular Receptor Model.
101. +-ATPase.
102. H.-D. Höltje and N. Dall, Pharmazie, 48, 243 (1993). A Molecular Modelling Study on the Hormone Binding Site of the Estrogen Receptor.
103. F. C. Bernstein, T. F. Koetzle, G. J. B. Williams, E. F. Meyer, Jr., M. D. Brice, J. R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tasumi, J. Mol. Biol., 112, 535 (1977). The Protein Data Bank: A Computer-Based Archival File for Macromolecular Structures.
104. F. H. Allen, S. Bellard, M. D. Brice, B. A. Cartwright, A. Doubleday, H. Higgs, T. Hummelink, B. G. Hummelink-Peters, O. Kennard, W. D. S. Motherwell, J. R. Rodgers, and D. G. Watson, Acta. Crystallogr., Sect. B, 35, 2331 (1979). The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information.
105. P. J. Goodford, J. Med. Chem., 28, 849 (1985). A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules.
106. J. P. Snyder, S. N. Rao, K. F. Koehler, and A. Vedani, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 336-354. Minireceptors and Pseudoreceptors.
107. J. W. Ponder and F. M. Richards, J. Mol. Biol., 193, 775 (1987). Tertiary Templates for Proteins.
108. A. Vedani, P. Zbinden, and J. P. Snyder, J. Receptor Res., 13, 163 (1993). Pseudo-receptor Modeling: A New Concept for the Three-Dimensional Construction of Receptor Binding Sites.
109. A. J. Hopfinger, J. Am. Chem. Soc., 102, 7196 (1980). A QSAR Investigation of Dihydrofolate Reductase Inhibition by Baker Triazines Based upon Molecular Shape Analysis.
110. B. J. Burke and A. J. Hopfinger, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 276-306. Advances in Molecular Shape Analysis.
111. A. J. Hopfinger, B. J. Burke, and W. J. Dunn III, J. Med. Chem., 37, 3768 (1994). A Generalized Formalism of Three-Dimensional Quantitative Structure-Property Relationship Analysis for Flexible Molecules Using Tensor Representation.
112. A. J. Hopfinger, Arch. Biochem. Biophys., 206, 153 (1981). A General QSAR for Dihydrofolate Reductase Inhibition by 2,4-Diaminotriazines Based upon Molecular Shape Analysis.
113. C. Battershell, D. Malhotra, and A. J. Hopfinger, J. Med. Chem., 24, 812 (1981). Inhibition of Dihydrofolate Reductase: Structure-Activity Correlations of Quinazolines Based upon Molecular Shape Analysis.
114. A. J. Hopfinger, J. Med. Chem., 24, 818 (1981). Inhibition of Dihydrofolate Reductase: Structure-Activity Correlations of 2,4-Diaminobenzylpyrimidines Based upon Molecular Shape Analysis.
115. A. J. Hopfinger and R. Potenzone, Mol. Pharmacol., 21, 187 (1982). Ames Test and Antitumor Activity of 1-(x-Phenyl)-3,3-dialkyltriazenes, Quantitative Structure-Activity Studies Based Upon Molecular Shape Analysis.
116. A. J. Hopfinger, J. Med. Chem., 26, 990 (1983). Theory and Application of Molecular Potential Energy Fields in Molecular Shape Analysis: A Quantitative Structure-Activity Relationship Study of 2,4-Diamino-5-benzylpyrimidines as Dihydrofolate Reductase Inhibitors.
117. S. N. Mohammad, D. R. Bickers, and A. J. Hopfinger, J. Theor. Biol., 102, 323 (1983). Intrinsic Mutagenicity of Polycyclic Aromatic Hydrocarbons: A Quantitative Structure-Activity Study Based upon Molecular Shape Analysis.
118. A. J. Hopfinger, Quant. Struct.-Act. Relat., 3, 1 (1984). A QSAR Study of the Ames Mutagenicity of 1-(x-Phenyl)-3,3-dialkyltriazenes Using Molecular Potential Energy Fields and Molecular Shape Analysis.
119. A. J. Hopfinger, D. Malhotra, R. D. Battershell, and A. W. Ho, Pestic. Sci., 9, 381 (1984). Conformational Behavior and Thermodynamic Properties of Phenothrin Analog Insecticides.
120. M. Mabilia, R. A. Pearlstein, and A. J. Hopfinger, Eur. J. Med. Chem., 20, 163 (1985). Molecular Shape Analysis and Energetics-Based Intermolecular Modelling of Benzylpyrimidine Dihydrofolate Reductase Inhibitors.
121. D. E. Walters and A. J. Hopfinger, J. Mol. Struct., 134, 317 (1986). Case Studies of the Application of Molecular Shape Analysis to Elucidate Drug Action.
122. M. G. Koehler, K. L. Rowberg-Schaefer, and A. J. Hopfinger, Arch. Biochem. Biophys., 266, 152 (1988). A Molecular Shape Analysis and Quantitative Structure-Activity Relationship Investigation of Some Triazine-Antifolate Inhibitors of Leishmania major Dihydrofolate Reductase.
123. B. J. Burke and A. J. Hopfinger, J. Med. Chem., 33, 274 (1990). 1-(Substituted-benzyl) imidazole-2-(3H)-thione Inhibitors of Dopamine β-hydroxylase.
124. M. G. Cardozo, Y. Iimura, H. Sugimoto, Y. Yamanishi, and A. J. Hopfinger, J. Med. Chem., 35, 584 (1992). QSAR Analyses of the Substituted Indanone and Benzyl Piperidine Rings of a Series of Indanone-benzylpipendine Inhibitors of Acetylcholinesterase.
125. M. G. Cardozo, T. Kawai, Y. Iimura, H. Sugimoto, Y. Yamanishi, and A. J. Hopfinger, J. Med. Chem., 35, 590 (1992). Conformational Analyses and Molecular-Shape Comparisons of a Series of Indanone-benzylpiperidine Inhibitors of Acetylcholinesterase.
126. J. S. Tokarsky and A. J. Hopfinger, J. Med. Chem., 37, 3639 (1944). Three-Dimensional Molecular Shape Analysis: Quantitative Structure-Activity Relationship of a Series of Cholecystokinin-A Receptor Antagonists.
127. K. A. Rowberg, E. M. Martin, and A. J. Hopfinger, J. Agric. Food Chem., 42, 374 (1994). QSAR and Molecular Shape Analyses of Three Series of 1-(Phenylcarbamoyl)-2-pyrazoline Insecticides.
128. B. J. Burke, W. J. Dunn III, and A. J. Hopfinger, J. Med. Chem., 37, 3775 (1994). Construction of a Molecular Shape Analysis: Three-Dimensional Quantitative Structure-Analysis Relationship for an Analog Series of Pyridobenzodiazepinone Inhibitors of Muscarinic 2 and 3 Receptors.
129. Z. Simon, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 307-319. MTD and Hyperstructure Approaches.
130. Z. Simon, A. Chiriac, I. Motoc, S. Holban, D. Ciubotariu, and Z. Szabadai, Stud. Biophys., 55, 217 (1976). Receptor Site Mapping. Search Strategy of Standard for Correlations with Minimal Steric Differences.
131. Z. Simon, N. Dragomir, M. G. Plauchitiu, S. Holban, H. Glatt, and F. Kerek, Eur. J. Med. Chem., 15, 521 (1980). Receptor Site Mapping for Cardiotoxic Aglycones by the Minimal Steric Difference Method.
132. A. Chiriac, V. Chiriac, D. Ciubotariu, S. Holban, and Z. Simon, Eur. J. Med. Chem., 18, 507 (1983). Minimal Steric Difference (MTD) Study for Flexible Molecules: Substituted Acetic Acid Derivatives with Auxinic Activity.
133. A. T. Balaban, I. Niculescu-Duvaz, and Z. Simon, Acta Pharm. Jugosl., 37, 7 (1986). Topological Aspects of QSAR for Biologically Active Molecules.
134. M. Bohl, Z. Simon, A. Vlad, G. Kaufmann, and K. Ponsold, Z. Naturforsch., 42c, 935 (1987). MTD Calculations on QSAR for Steroid Binding to Progesterone Receptor.
135. M. Apetroaie, C. Singer, R. Bozga, S. Cilianu, R. Ceclan, T. Banzaru, and Z. Simon, Rev. Roum. Chim., 32, 583 (1987). Structure-Activity Relations by the Free-Wilson and MTD Methods for Substances with Potential Psychotropic Activity. I. Diphenylether Derivatives with Neuroleptic Activity.
136. Z. Simon, G. I. Mihalas, M. Apetroaie, C. Singer, R. Bozga, and S. Cilianu, Rev. Roum. Chim., 32, 783 (1987). Structure-Activity Relations by the Free-Wilson and MTD Methods for Substances with Potential Psychotropic Activity. II. Benzenesulfonamide Derivatives with Anticonvulsive Activity.
137. I. Gergen, Z. Simon, and J. R. Lochmann, Z. Naturforsch., 44c, 217 (1989). Theoretical Investigations on Steroid Skeleton C-4=C-5 Unsaturation in Competitive Aromatase Inhibition.
138. I. Gergen, M. Bohl, H. Simon, and Z. Simon, Rev. Roum. Chim., 34, 995 (1989). Structure-Activity Relations for Steroids by the MTD-Method. Superimposition Procedure for Molecules with Different Condensed Cycles.
139. A. Motsenigos, D. Ciubotariu, A. Chiriac, and Z. Simon, Rev. Roum. Chim., 34, 2101 (1989). Alpha Adrenergic Clonidine Derivatives, QSAR by MTD for Multiconformational Molecules.
140. Z. Simon and M. Bohl, Quant. Struct.-Act. Relat., 11, 23 (1992). Structure-Activity Relations in Gestagenic Steroids by the MTD Method. The Case of Hard Molecules and Soft Receptors.
141. T. Oprea, D. Ciubotariu, T. Sulea, and Z. Simon, Quant. Struct.-Act. Relat., 12, 21 (1993). Comparative Analysis by MTD and CoMFA for Binding of Steroids to Carrier Proteins.
142. D. Ciubotariu, E. Deretey, T. I. Oprea, T. Sulea, Z. Simon, L. Kurunczi, and A. Chiriac, Quant. Struct.-Act. Relat., 12, 367 (1993). Multiconformational Minimal Steric Difference. Structure-Acetylcholinesterase Hydrolysis Rates Relations for Acetic Acid Esters.
143. S. Muresan, C. Bologa, A. Chinac, B. Jastorff, L. Kurunczi, and Z. Simon, Quant. Struct.-Act. Relat., 13, 242 (1994). Comparative Structure-Affinity Relations by MTD for Binding of Cycloadenosine Monophosphate Derivatives to Protein Kinase Receptors.
144. Z. Simon, A. Chiriac, S. Holban, D. Ciubotariu, and G. I. Mihalas, Minimum Steric Difference. The MTD-Method for QSAR Studies, Research Studies Press, Letchworth, UK, 1994.
145. I. Motoc, Math. Chem., 5, 275 (1979). On the MTD Method. 1. Critical Evaluation and Improvement.
146. R. D. Cramer III, D. E. Patterson, and J. D. Bunce, J. Am. Chem. Soc., 110, 5959 (1988). Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins.
147. G. M. Crippen, J. Comput. Phys., 24, 96 (1977). A Novel Approach to Calculation of Conformation: Distance Geometry.
148. A. K. Ghose and G. M. Crippen, in Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study, and Therapeutic Application of Chemical Compounds, C. A. Ramsden, Ed., Pergamon Press, Oxford, 1990, Vol. 4, pp. 715-753. The Distance Geometry Approach to Modeling Receptor Sites.
149. S. Srivastava, W. W. Richardson, M. P. Bradley, and G. M. Crippen, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 409-430. Three-Dimensional Receptor Modeling Using Distance Geometry and Voronoi Polyhedra.
150. G. M. Crippen, J. Med. Chem., 22, 988 (1979). Distance Geometry Approach to Rationalizing Binding Data.
151. G. M. Crippen, J. Med. Chem., 23, 599 (1980). Quantitative Structure-Activity Relationships by Distance Geometry: Systematic Analysis of Dihydrofolate Reductase Inhibitors.
152. G. M. Crippen, J. Med. Chem., 24, 198 (1981). Quantitative Structure-Activity Relationships by Distance Geometry: Thyroxine Binding Site.
153. G. Crippen, Mol. Pharmacol., 22, 11 (1982). Distance Geometry Analysis of the Benzodiazepine Binding Site.
154. A. K. Ghose and G. M. Crippen, J. Med. Chem., 25, 892 (1982). Quantitative Structure-Activity Relationship by Distance Geometry: Quinazolines as Dihydrofolate Reductase Inhibitors.
155. A. K. Ghose and G. M. Crippen, J. Med. Chem., 26, 996 (1983). Combined Distance Geometry Analysis of Dihydrofolate Reductase Inhibition by Quinazolines and Triazines.
156. A. K. Ghose and G. M. Crippen, J. Med. Chem., 27, 901 (1984). General Distance Geometry Three-Dimensional Receptor Model for Diverse Dihydrofolate Reductase Inhibitors.
157. A. K. Ghose and G. M. Crippen, J. Med. Chem., 28, 333 (1985). Use of Physicochemical Parameters in Distance Geometry and Related Three-Dimensional Quantitative Structure-Activity Relationships: A Demonstration Using Escherichia Coli Dihydrofolate Reductase Inhibitors.
158. A. Ghose, G. Crippen, G. R. Revankar, P. McKernan, D. Smee, and R. Robins, J. Med. Chem., 32, 746 (1989). Analysis of the In Vitro Activity of Certain Ribonucleosides Against Parinfluenza Virus Using a Novel Computer-Aided Molecular Modeling Procedure.
159. A. K. Ghose, V. N. Viswanadhan, Y. S. Sangvi, L. D. Nord, R. C. Willis, G. R. Revankar, and R. K. Robins, Proc. Natl. Acad. Sci. USA, 86, 8242 (1989). Structural Mimicry of Adenosine by Antitumor Agents 4-Methoxy- and 4-Amino-8-(β-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidines as Viewed by a Molecular Modeling Method.
160. A. K. Ghose and G. M. Crippen, Mol. Pharmacol., 37, 725 (1990). Modeling the Benzodiazepine Receptor Binding Site by the General Three-Dimensional Structure-Directed Quantitative Structure-Activity Relationship Method REMOTEDISC.
161. V. N. Viswanadhan, A. K. Ghose, N. B. Hanna, S. S. Matsumoto, T. L. Avery, G. R. Revankar, and R. K. Robins, J. Med. Chem., 34, 526 (1991). Analysis of the In Vitro Antitumor Activity of Novel Purine-6-sulfenamide, -sulfinamide, and -sulfonamide Nucleosides and Certain Related Compounds Using a Computer-Aided Receptor Modeling Procedure.
162. G. M. Crippen, J. Comput. Chem., 8, 943 (1987). Voronoi Binding Site Models.
163. L. G. Boulu and M. G. Crippen, J. Comput. Chem., 10, 673 (1989). Voronoi Binding Site Models: Calculation of Binding Modes and Influence of Drug Binding Data Accuracy.
164. L. G. Boulu, G. M. Crippen, H. A. Barton, H. Kwon, and M. A. Marletta, J. Med. Chem., 33, 771 (1990). Voronoi Binding Site Model of a Polycyclic Aromatic Hydrocarbon Binding Protein.
165. U. Thibaut, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 661-696. Applications of CoMFA and Related 3D QSAR Approaches.
166. Y. C. Martin, K.-H. Kim, and C. T. Lin, in Advances in Quantitative Structure Property Relationships, M. Charron, Ed., JAI Press, Greenwich, CT, 1996, Vol. 1, pp. 1-52. Comparative Molecular Field Analysis: CoMFA.
167. R. D. Cramer III, S. A. DePriest, D. E. Patterson, and P. Hecht, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 443-485. The Developing Practice of Comparative Molecular Field Analysis.
168. G. Folkers, A. Merz, and D. Rognan, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 583-618. CoMFA: Scope and Limitations.
169. Y. C. Martin, C. T. Lin, and J. Wu, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 643-660. Application of CoMFA to the Design and Structural Optimization of D1 Dopaminergic Agonists.
170. H. Van de Waterbeemd, S. Clementi, G. Costantino, P.-A. Carrupt, and B. Testa, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 697-707. CoMFA-derived Substituent Descriptors for Structure-Property Correlations.
171. Y. C. Martin and C. T. Lin, in The Practice of Medicinal Chemistry, C.-G. Wermuth, Ed., Academic Press, London, 1996, pp. 459-483. Three-Dimensional Quantitative Structure-Activity Relationships: D2 Dopamine Agonists as an Example.
172. K. H. Kim, Quant. Struct.-Act. Relat., 12, 232 (1993). 3D-Quantitative Structure-Activity Relationships: Describing Hydrophobic Interactions Directly from 3D Structures Using a Comparative Molecular-Field Analysis (CoMFA) Approach.
173. C. Tanford, The Hydrophobic Effect: Formation of Micelles and Biological Membranes, Wiley-Interscience, New York, 1973.
174. M. C. Nicklaus, H. Ford Jr., L. Hegedus, G. W. A. Milne, and J. A. Kelley, Quant. Struct. Act. Relat., 14, 335 (1995). Comparative Molecular-Field Analysis of Hydrophobicity Descriptors of Cytosine Nucleosides.
175. G. E. Kellogg, S. F. Semus, and D. J. Abraham, J. Comput.-Aided Mol. Design, 5, 545 (1991). HINT: A New Method of Empirical Hydrophobic Field Calculations for CoMFA.
176. D. J. Abraham and G. E. Kellogg, J. Comput.-Aided Mol. Design, 8, 41 (1994). The Effect of Physical Organic Properties on Hydrophobic Fields.
177. C. L. Waller, D. L. Minor, and J. D. McKinney, Environ. Health Perspect., 103, 7 (1995). Using 3-Dimensional Quantitative Structure-Activity Relationships to Examine Estrogen-Receptor Binding Affinities of Polychlorinated Hydroxybiphenyls.
178. B. Testa, P.-A. Carrupt, P. Gaillard, F. Billois, and P. Weber, Pharm. Res., 13, 335 (1996). Lipophilicity in Molecular Modeling. See also, P.-A. Carrupt, B. Testa, and P. Gaillard, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 241-315. Computational Approaches to Lipophilicity: Methods and Applications.
179. B. Testa, P.-A. Carrupt, P. Gaillard, F. Billois, and P. Weber, Pharm. Res., 13, 335 (1996). Lipophilicity in Molecular Modeling. See also, P.-A. Carrupt, B. Testa, and P. Gaillard, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 241-315. Computational Approaches to Lipophilicity: Methods and Applications.
180. A. M. Davis, N. P. Gensmantel, E. Johansson, and D. P. Marriot, J. Med. Chem., 37, 963 (1994). The Use of the GRID Program in the 3-D QSAR Analysis of a Series of Calcium-Channel Agonists.
181. J. P. Horwitz, I. Massova, T. E. Wiese, B. H. Besler, and T. H. Corbett, J. Med. Chem., 37, 781 (1994). Comparative Molecular Field Analysis of the Antitumor Activity of 9H-Thioxanthen-9-one Derivatives Against Pancreatic Ductal Carcinoma 03.
182. M. S. Searle and D. H. Williams, J. Am. Chem. Soc., 114, 10690 (1992). The Cost of Conformational Order: Entropy Changes in Molecular Associations.
183. S. A. DePriest, D. Mayer, C. B. Naylor, and G. R. Marshall, J Am. Chem. Soc., 115, 5372 (1993). 3D-QSAR of Angiotensin-Converting Enzyme and Thermolysin Inhibitors - A Comparison of CoMFA Models Based on Deduced and Experimentally Determined ActiveSite Geometries.
184. G. Greco, E. Novellino, C. Silipo, and A. Vittoria, Quant. Struct.-Act. Relat., 10, 289 (1991). Comparative Molecular Field Analysis on a Set of Muscarinic Agents.
185. G. Klebe, U. Abraham, and T. Mietzner, J. Med. Chem., 37, 4130 (1994). Molecular Similarity Indices in a Comparative Molecular Field Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological Activity.
186. G. Greco, E. Novellino, M. Pellecchia, C. Silipo, and A. Vittoria, J. Comput.-Aided Mol. Design, 8, 97 (1994). Effects of Variable Selection on CoMFA Coefficient Contour Maps in a Set of Triazines Inhibiting DHFR.
187. U. Thibaut, G. Folkers, G. Klebe, H. Kubinyi, A. Merz, and D. Rognan, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 711-716. Recommendations for CoMFA.
188. G. D. Diana, P. Kowalczyk, A. M. Treasurywala, R. C. Oglesby, D. C. Pevear and F. J. Dutko, J. Med. Chem., 35, 1002 (1992). CoMFA Analysis of the Interactions of Antipicornavirus Compounds in the Binding Pocket of Human Rhinovirus-14.
189. A. Doweyko, HASL, Hypothesis Software, P.O. Box 237, Long Valley, NJ 07853-0237. E-mail: hyposoft@cris.com.
190. M. Wiese, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 431-442. The Hypothetical Active-Site Lattice.
191. M. Wiese and E. A. Coats, in QSAR: Rational Approaches to the Design of Bioactive Compounds, C. Silipo and A. Vittoria, Eds., Elsevier, Amsterdam, 1991, pp. 343-346. A New Combination of HASL and PLS for Receptor Mapping.
192. A. M. Doweyko, J. Med. Chem., 37, 1769 (1994). Three-Dimensional Pharmacophores from Binding Data.
193. A. C. Good, S. J. Peterson, and W. G. Richards, J. Med. Chem., 36, 2929 (1993). QSARs from Similarity Matrices-Technique Validation and Application in the Comparison of Different Similarity Evaluation Methods.
194. A. Sen-Levy, S. West, and W. G. Richards, J. Med. Chem., 37, 1727 (1994). Molecular Similarity Quantitative Chirality, and QSAR for Chiral Drugs.
195. Y. C. Martin, C. T. Lin, C. Hetti, and J. DeLazzer, J. Med. Chem., 38, 3009 (1995). PLS Analysis of Distance Matrices to Detect Nonlinear Relationships Between Biological Potency and Molecular Properties.
196. R. Carbo, L. Leyda, and M. Arnau, Int. J. Quantum Chem., 17, 1185 (1980). An Electron Density Measure of the Similarity Between Two Compounds.
197. E. E. Hodgkin and W. G. Richards, Int. J. Quantum Chem., 14, 105 (1987). Molecular Similarity Based on Electrostatic Potential and Electric Field.
198. A. M. Meyer and W. G. Richards, J. Comput.-Aided Mol. Design, 5, 426 (1991). Similarity of Molecular Shape.
199. A. C. Good, E. E. Hodgkin, and W. G. Richards, J. Chem. Inf. Comput. Sci., 32, 188 (1992). The Utilization of Gaussian Functions for the Rapid Evaluation of Molecular Similarity.
200. A. C. Good and W. G. Richards, J. Chem. Inf. Comput. Sci., 33, 112 (1993). Rapid Evaluation of Shape Similarity Using Gaussian Functions.
201. A. Höskuldson, J. Chemometrics. 2, 211 (1988). PLS Regression Methods.
202. R. Benigni and A. Giuliani, Quant. Struct.-Act. Relat., 12, 397 (1993). Analysis of Distance Matrices for Studying Data Structures and Separating Classes.
203. H. Kubinyi, QSAR: Hansch Analysis and Related Approaches, VCH Publishers, Weinheim, 1993, Vol. 1.
204. 1A Receptor.
205. D. E. Walters and R. M. Hinds, J. Med. Chem., 37, 2527 (1994). Genetically Evolved Receptor Models: A Computational Approach to Construction of Receptor Models.
206. B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, J. Comput. Chem., 4, 187 (1983). CHARMM: A Program for Macromolecular Energy Minimization, and Dynamics Calculations.
207. Y. C. Martin, unpublished observations (1996). Preliminary investigations of GERM.
208. G. Moreau and P. Broto, Nouv. Chim., 11, 127 (1984). The Autocorrelation of a Topological Structure: A New Molecular Descriptor.
209. G. Moreau and C. Turpin, Analusis, 24, M17 (1996). Use of Similarity Analysis to Reduce Large Molecular Libraries to Smaller Sets of Representative Molecules.
210. M. Wagener, J. Sadowski, and J. Gasteiger, J. Am. Chem. Soc., 117, 7769 (1995). Autocorrelation of Molecular Surface Properties for Modeling Corticosteroid Binding Globulin and Cytosolic AH Receptor Activity by Neural Networks.
211. S. Clementi, G. Cruciani, D. Riganelli, R. Valigi, G. Constantino, M. Baroni, and S. Wold, Pharm. Pharmacol. Lett., 3, 5 (1993). Autocorrelation as a Tool for a Congruent Description of Molecules in 3D-QSAR Studies.
212. W. Heiden, G. Moeckel, and J. Brickmann, J. Comput.-Aided Mol. Design, 7, 503 (1993). A New Approach to Analysis and Display of Local Lipophilicity/Hydrophilicity Mapped on Molecular Surfaces.
213. M. Hahn and D. Rogers, J. Med. Chem., 38, 2091 (1995). Receptor Surface Models. 2. Application to Quantitative Structure-Activity Relationships Studies.
214. M. Hahn, J. Med. Chem., 38, 2080 (1995). Receptor Surface Models. 1. Definition and Construction.
215. B. D. Silverman and D. E. Platt, J. Med. Chem., 39, 2129 (1996). Comparative Molecular Moment Analysis (CoMMA) - 3D-QSAR Without Molecular Superposition.
216. Ajay and M. A. Murcko, J. Med. Chem., 38, 4953 (1995). Computational Methods to Predict Binding Free-Energy in Ligand-Receptor Complexes.
217. S. Dixon and J. Blaney, in Designing Bioactive Molecules: Three-Dimensional Techniques and Applications, Y. C. Martin and P. Willett, Eds., American Chemical Society, Washington, DC, 1997, in press. Docking.
218. J. M. Blaney and J. S. Dixon, Perspect. Drug Discovery Design, 1, 301 (1993). A Good Ligand Is Hard to Find: Automated Docking Methods.
219. C. L. Waller and G. R. Marshall, J. Med. Chem., 36, 2390 (1993). Three-Dimensional Quantitative Structure-Activity Relationship of Angiotensin-Converting Enzyme and Thermolysin Inhibitors. II. A Comparison of CoMFA Models Incorporating Molecular-Orbital Fields and Desolvation Free-Energies Based on Active-Analog and Complementary-Receptor Field Alignment Rules.
220. C. L. Waller, T. I. Oprea, A. Giolitti, and G. R. Marshall, J. Med. Chem., 36, 4152 (1993). Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules.
221. K. A. Watson, E. P. Mitchell, L. N. Johnson, G. Cruciani, J. C. Son, C. J. F. Bichard, G. W. J. Fleet, N. G. Oikonomakos, M. Kontou, and S. E. Zographos, Acta Crystallogr., Sect. D, 51, 458 (1995). Glucose Analog Inhibitors of Glycogen-phosphorylase - From Crystallographic Analysis to Drug Prediction Using GRID Force Field and GOLPE Variable Selection.
222. J. M. Blaney, P. K. Weiner, A. Dearing, P. A. Kollman, E. C. Jorgensen, S. J. Oatley, J. M. Burridge, and C. C. F. Blake, J. Am. Chem. Soc., 104, 6424 (1982). Molecular Mechanics Simulation of Prorein-Ligand Interactions: Binding of Thyroid Hormone Analogues to Prealbumin.
223. M. C. Menziani, P. G. D. Benedetti, F. Gago, and W. G. Richards, J. Med. Chem., 32, 951 (1989). The Binding of Benzenesulfonamides to Carbonic Anhydrase Enzyme. A Molecular Mechanics Study and Quantitative Structure-Activity Relationships.
224. M. K. Holloway, J. M. Wai, T. A. Halgren, P. M. D. Fitzgerald, J. P. Vacca, B. D. Dorsey, R. B. Levin, W. J. Thompson, L. J. Chen, S. J. deSolms, N. Gaffin, A. K. Ghosh, E. A. Giuliani, S. L. Graham, J. P. Guare, R. W. Hungate, T. A. Lyle, W. M. Sanders, T. J. Tucker, M. Wiggins, C. M. Wiscount, O. W. Woltersdorf, S. D. Young, P. L. Darke, and J. A. Zugay, J. Med. Chem., 38, 305 (1995). A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site.
225. T. A. Halgren, J. Comput. Chem., 17, 490 (1996). Merck Molecular Force Field. I. Basis, Form, Scope, Parameterization, and Performance of MMFF94.
226. J. Åqvist, G. Medina, and J.-E. Samuelsson, Protein Eng., 7, 385 (1994). A New Method for Predicting Binding Affinity in Computer-Aided Drug Design.
227. J. Åqvist and S. L. Mowbray, J. Biol. Chem., 270, 9978 (1995). Sugar Recognition by a Glucose/Galactose Receptor. Evaluation of Binding Energetics from Molecular Dynamics Simulations.
228. M. D. Paulsen and R. L. Ornstein, Protein Eng., 9, 567 (1996). Binding Free-Energy Calculations for P450cam-Substrate Complexes.
229. N. R. Taylor and M. von Itzstein, J. Comput.-Aided Mol. Design, 10, 233 (1996). A Structural and Energetics Analysis of the Binding of a Series of N-Acetylneuramimc-Acid-Based Inhibitors to Influenza Virus Sialidase.
230. DelPhi, Molecular Simulations, Inc. (formerly BIOSYM Technologies), San Diego, CA.
231. I. T. Weber and R. W. Harrison, Protein Eng., 9, 679 (1996). Molecular Mechanics Calculations on HIV-1 Protease with Peptide-Substrates Correlate with Experimental Data.
232. M. A. Murcko, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 1-66. Recent Advances in Ligand Design Methods. D. E. Clark, C. W. Murray and J. Li, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 67-125. Current Issues in De Novo Molecular Design.
233. M. A. Murcko, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 1-66. Recent Advances in Ligand Design Methods. D. E. Clark, C. W. Murray and J. Li, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., Wiley-VCH, New York, 1997, Vol. 11, pp. 67-125. Current Issues in De Novo Molecular Design.
234. H.-J. Böhm, J. Comput.-Aided Mol. Design, 6, 593 (1992). Rule-Based Automated Design of New Substituents for Enzyme Inhibitor Leads.
235. H.-J. Böhm, J. Comput.-Aide Mol. Design, 8, 243 (1994). The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protem-Ligand Complex of Known Three-Dimensional Structure.
236. R. S. Bohacek and C. McMartin, J. Med. Chem., 35, 1671 (1992). Definition and Display of Steric, Hydrophobic, and Hydrogen-Bonding Properties of Ligand Binding Sites in Proteins Using Lee and Richards Accessible Surface: Validation of a High-Resolution Graphical Tool for Drug Design.
237. G. Verkhivker, K. Appelt, S. T. Freer, and J. E. Villafranca, Protein Eng., 8, 677 (1995). Empirical Free-Energy Calculations of Ligand-Protein Crystallographic Complexes. 1. Knowledge-Based Ligand-Protein Interaction Potentials Applied to the Prediction of Human-Immunodeficiency-Virus-1 Protease Binding Affinity.
238. R. D. Held, M. L. Smythe, T. I. Oprea, C. L. Waller, S. M. Green, and G. R. Marshall, J. Am. Chem. Soc., 118, 3959 (1996). VALIDATE - A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands.
239. D. A. Gschwend, A. C. Good, and I. D. Kuntz, J. Mol. Recognition, 9, 175 (1996). Molecular Docking Towards Drug Discovery.
240. A. C. Good and J. S. Mason, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1996, Vol. 7, pp. 67-117. Three-Dimensional Structure Database Searches.
241. Y. C. Martin, M. G. Bures, and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1990, Vol. 1, pp. 213-263. Searching Databases of Three-Dimensional Structures. G. M. Downs and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1995, Vol. 7, pp. 1-66. Similarity Searching in Databases of Chemical Structures.
242. Y. C. Martin, M. G. Bures, and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1990, Vol. 1, pp. 213-263. Searching Databases of Three-Dimensional Structures. G. M. Downs and P. Willett, in Reviews in Computational Chemistry, K. B. Lipkowitz and D. B. Boyd, Eds., VCH Publishers, New York, 1995, Vol. 7, pp. 1-66. Similarity Searching in Databases of Chemical Structures.
243. V. J. Gillet and A. P. Johnson, in Designing Bioactive Molecules:Three-Dnnensional Techniques and Applications, Y. C. Martin and P. Willett, Eds., American Chemical Society, Washington, DC, 1997, in press. Structure Generation.
244. S. Clementi, G. Cruciani, M. Baroni, and G. Costantino, in 3D QSAR in Drug Design: Theory, Methods and Applications, H. Kubinyi, Ed., ESCOM, Leiden, 1993, pp. 567-582. Series Design.